Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
August 27, 2024 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted...
Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update
August 15, 2024 07:00 ET
|
Portage Biotech Inc.
Exploration and evaluation of strategic alternatives continuePausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)Discontinuing the iNKT clinical trial for...
Portage Biotech Announces 1-for-20 Reverse Stock Split
August 13, 2024 07:00 ET
|
Portage Biotech Inc.
Portage Biotech Announces 1-for-20 Reverse Stock Split effective with the opening of trading on August 15, 2024, on The Nasdaq Capital Market
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
April 12, 2024 08:01 ET
|
Portage Biotech Inc.
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-Adenosine clinical development paused
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
March 26, 2024 08:01 ET
|
Portage Biotech Inc.
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
February 28, 2024 17:10 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Company focused on adenosine platform clinical development
Portage Biotech Reports Business and Strategic Update
January 04, 2024 08:00 ET
|
Portage Biotech Inc.
Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) --...
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
November 28, 2023 16:01 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 06, 2023 08:01 ET
|
Portage Biotech Inc.
Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanomaStrong academic...
Portage Biotech Announces $6.0 Million Registered Direct Offering
September 29, 2023 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents...